$LQDA

Bloch Stephen M sold $6.3M of LQDA (indirect holdings)

Bloch Stephen M sold 78,596 indirectly-held shares of Liquidia Corp (LQDA) at an average of $79.97 ($79.55–$80.66, $6.29M total) across 3 trades over 2026-07-20 to 2026-07-21.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Jul 22, 2026, 11:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 22, 2026, 11:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The only new information is the disclosed sale details (shares, price range, total value, post-transaction holdings).

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not provide a new fundamental catalyst.

03

What to watch

The article notes no 10b5-1 plan, but it does not provide the director’s broader holdings, tax/liquidity needs, or whether other insiders made offsetting purchases.

Relevance 6/10Novelty 3/10Timing: new SEC Form 4 filed 2026-07-22 for sales executed 2026-07-20 to 2026-07-21

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Liquidia Corp.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia director Stephen M. Bloch sold 78,596 shares in open-market trades for about $6.29M, per a new SEC Form 4 filing.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than based on new company performance data.

Evidence & confidence

The filing discloses transaction size, dates, and price range, but provides no new operational, regulatory, or financial catalyst for Liquidia.

Market effects

Minimal; insider sale in a single biotech does not imply sector-wide changes.

None indicated.

None indicated.

Counterpoint

Director sales can be routine liquidity events and may not reflect bearish expectations, especially without any accompanying negative company news.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider sale disclosure (LQDA).

  • Bloch Stephen M

    Director who sold shares via open-market transactions; indirect holdings reported.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient